Global Markets for Blood Plasma Products to Reach $23B by 2021

August 08, 2017

WELLESLEY, Mass., Aug 8, 2017 – Rising demand for immunoglobulins is the main driver of the global market for blood plasma products, which has the potential to reach $23 billion by 2021. In a new report, BCC Research studies the industry’s prospects through different perspectives, including product applications, end user consumption, and global market analysis.

Deficiencies in a blood plasma component can result in the onset of disease, which has led to acceleration in both basic and targeted R&D in this area. Blood plasma is a part of effective treatment for several chronic and life-threatening diseases such as hemophilia, leukemia, and immunodeficiency disorders. Blood plasma products have proven to be a boon for patients suffering from such diseases. From approximately $16.8 billion in 2016 sales, product launches and improvements in existing technologies will expand this industry through 2021, according to the report Global Markets for Blood Plasma Products.

The United States leads the market due to the surging demand for hemophilia therapies. The Asia-Pacific region, led by China, held the second largest market share in 2016.

Research Highlights

  • Plasma products are key in the burgeoning field of immunotherapy. Immunoglobulins play a crucial role in the treatment of immunocompromised patients.
  • The majority of markets in the Asia-Pacific and Rest of the World regions are untapped and thus provide opportunities for manufacturers of blood plasma products to expand their businesses.
  • In addition, China has adopted several plasma fractionation technologies to ensure sufficient blood plasma supply throughout Asia.

Concerns Include High Costs, Safety

“Immunodeficiency is a significant concern in various regions of the world and is expected to drive growth in the global market for blood plasma products,” says Yojana Jeevane, BCC Research analyst and of this report. “Two major restraining factors are the high costs associated with these therapies and the threat of transmission of blood-borne diseases. Ensuring safety as well as efficacy during blood donations and transfusions will be paramount.”

Editors/reporters requesting analyst interviews should contact

Global Markets for Blood Plasma Products( HLC201A )
Publish Date: Jul 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.